Glenmark Therapeutics Inc., USA Launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC)

Glenmark Therapeutics Inc., USA has announced the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC), an over-the-counter product that is a therapeutic equivalent to MiraLAX®2 Powder for Solution, 17 grams of Bayer HealthCare LLC. The product is launched in response to the growing demand for a new supplier in this category, aiming to meet market needs and provide high-quality solutions for customers. The MiralAX® Powder for Solution, 17 grams (OTC) market achieved annual sales of approximately $555.7 million*. Glenmark Pharmaceuticals Ltd., the parent company, is a research-led, global pharmaceutical company with a presence across Branded, Generics, and OTC segments, and operations in over 80 countries.